Bone Therapeutics Names Lieve Creten Interim CFO; Effective Sept. 21

Gosselies-headquartered Bone Therapeutics (BOTHE), a biotech company, on Tuesday, said it has appointed Lieve Creten as its interim Chief Financial Officer or CFO, replacing Jean-Luc Vandebroek, effective from September 21.

Bone Therapeutics has already initiated the recruitment efforts for a permanent CFO and will make an announcement in due course, the company said in a statement.

The Belgian firm has agreed to a planned transition of Vandebroek's tenure as CFO during the fourth quarter of 2021. This will enable him to pursue new opportunities outside the company from the end of the year.

Despite his resignation, Vandebroek is expected to remain on the board of directors of the company as a non-executive director and support a managed transition of the CFO function.

Vandebroek served Bone Therapeutics for over four years. During his tenure, he was instrumental in securing the necessary financing for the company and leaves behind strong investor relations ready to support the company's growth plans for the next years.

Creten will be deployed to ensure optimal financial control, oversight, and compliance during Bone Therapeutics strategic refocus on the iMSC platform, which includes its product ALLOB, the company said.

Creten has vast experience in management, financial reporting, and business deals including acquisitions and mergers for both public and private companies, as the Belgian company strategically realigns to fully focus on its iMSC cell and gene therapy platform of professional mesenchymal stromal cells (MSCs) for a wider range of therapeutic targets, Bone Therapeutics added.

For comments and feedback contact: editorial@rttnews.com

Follow RTT